|
1）Leoncini L, Raphael M, Stein H, et al. Burkitt lymphoma. In: Swerdlow SH, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed. Lyon: IARC press; 2008. p.262-4
|
|
|
|
|
2）Hummel M, Bentink S, Berger H, et al. A biological definition of Burkittʼs lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006; 354: 2419-30
|
|
|
|
|
3）Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkittʼs lymphoma. N Engl J Med. 2006; 354: 2431-42
|
|
|
|
|
|
4）Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012; 490: 116-20
|
|
|
|
|
|
5）Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012; 44: 1316-20
|
|
|
|
|
|
6）Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012; 44: 1321-5
|
|
|
|
|
|
7）Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009; 139: 573-86
|
|
|
|
|
|
8）Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463: 88-92
|
|
|
|
|
|
9）Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012; 22: 167-79
|
|
|
|
|